关注
Luca Maini
Luca Maini
Assistant Professor, Harvard Medical School
在 hcp.med.harvard.edu 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Has the era of slow growth for prescription drug spending ended?
M Aitken, ER Berndt, D Cutler, M Kleinrock, L Maini
Health Affairs 35 (9), 1595-1603, 2016
442016
Reference pricing as a deterrent to entry: evidence from the European pharmaceutical market
L Maini, F Pammolli
American Economic Journal: Microeconomics 15 (2), 345-383, 2023
412023
Price increases of protected-class drugs in Medicare Part D, relative to inflation, 2012-2017
TJ Hwang, SB Dusetzina, J Feng, L Maini, AS Kesselheim
JAMA 322 (3), 267-269, 2019
262019
Profiting from Most-Favored Customer Procurement Rules: Evidence from Medicaid
J Feng, T Hwang, L Maini
American Economic Journal: Economic Policy 15 (2), 166-197, 2023
9*2023
Demand Inertia and the Hidden Impact of Pharmacy Benefit Managers
J Feng, L Maini
Management Science, 2024
62024
Biosimilar entry and the pricing of biologic drugs
L Maini, J Feng, T Hwang, J Klimek
Available at SSRN 3760213, 2021
62021
Medicaid expenditures and estimated rebates on line extension drugs, 2010–2018
TJ Hwang, J Feng, L Maini, AS Kesselheim
Journal of General Internal Medicine 37 (14), 3769-3771, 2022
52022
Where is the good stuff? Drug quality measures and economic research
J Feng, L Maini
Harvard University working paper, 2016
22016
Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition
K Feng, M Russo, L Maini, AS Kesselheim, BN Rome
JAMA Health Forum 5 (3), e235429-e235429, 2024
12024
Stocking Under the Influence: Spillovers from Commercial Drug Coverage to Medicare Utilization
EB Dean, J Feng, L Maini
Available at SSRN 4578352, 2023
12023
Mergers that Matter: The Impact of M&A Activity in Prescription Drug Markets
J Feng, T Hwang, Y Liu, L Maini
Tech. rep., University of Utah, 2023
12023
Benefit Design And Biosimilar Coverage In Medicare Part D: Evidence And Implications From Recent Reforms
L Bertuzzi, L Maini
Health Affairs 43 (5), 717-724, 2024
2024
Impact of Including Drug Spending in Oncology Alternative Payment Models
L Maini, JP Klimek, DC Johnson, GM Holmes, DA DeWalt
The American Journal of Managed Care, 2023
2023
系统目前无法执行此操作,请稍后再试。
文章 1–13